No Data
Sutro Biopharma Announces Poster Presentations To Highlight Its Next-Generation Exatecan And Dual-Payload ADC Programs At Upcoming American Association for Cancer Research April 25-30 In Chicago, Illinois
Lacklustre Performance Is Driving Sutro Biopharma, Inc.'s (NASDAQ:STRO) 36% Price Drop
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn
12 Health Care Stocks Moving In Monday's Intraday Session
New Analyst Forecast: $STRO Given $2.0 Price Target
H.C. Wainwright Downgrades Sutro Biopharma(STRO.US) to Hold Rating, Cuts Target Price to $2